{"product_id":"alliancepharmaplc-five-forces-analysis","title":"Alliance Pharma Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlliance Pharma faces moderate buyer power, patchwork supplier influence, and intense rivalry in branded OTC and specialty pharma niches, while regulatory hurdles and capital requirements temper new entrants and substitute threats—creating a nuanced competitive landscape. This brief highlights key pressures and strategic levers; unlock the full Porter's Five Forces Analysis for force-by-force ratings, visuals, and actionable recommendations to inform investment or strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated API and CMO base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlliance depends on a finite pool of qualified API suppliers and CMOs for regulated Rx lines, with China and India together supplying the majority of global APIs by 2024, constraining alternative sources. Supplier consolidation and stringent regulatory approvals raise switching costs, giving suppliers price leverage and tighter service terms. Dual-sourcing is used as mitigation but is costly and time-consuming to implement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality gatekeeping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQualified suppliers hold critical GMP certifications and regulatory dossiers, and any warning letter can halt supply instantly, giving those suppliers outsized leverage; revalidations commonly take 3–6 months in 2024, materially raising switching costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized packaging and medical devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCertain brands require bespoke packaging or device components with limited alternate sources; tooling often runs $50k–$250k and MOQs commonly range 10k–100k. Lead times of 12–26 weeks lock in relationships and raise switching costs. Supplier surveys in 2023–24 indicated roughly 60% of input inflation was passed through to buyers. Alliance must balance inventory risk against negotiating cost concessions and volume commitments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand\/licensing dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsome alliance pharma skus remain licensed from originators holding ip or know-how and royalty norms plus tech-transfer limits restricted data access materially strengthen supplier bargaining power. delays of months renewal uplifts have been observed in tightening margins diversifying brand ownership reduces this exposure.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensed SKUs: dependency risk\u003c\/li\u003e\n\u003cli\u003eRoyalty rates 5–12% (2024)\u003c\/li\u003e\n\u003cli\u003eTech-transfer delays 6–12 months\u003c\/li\u003e\n\u003cli\u003eRenewal cost uplifts 5–15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psome\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput cost volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFX, energy and commodity swings (Brent c.86 USD\/bbl in 2024, GBP\/USD c.1.27 average in 2024) ripple through supplier pricing, and CMOs commonly embed indexation clauses to protect margins.\u003c\/p\u003e\n\u003cp\u003eRetail channel pass-through often lags by 2–6 months, compressing distributors’ margins and strengthening suppliers’ bargaining position as timing gaps shift working capital risk upstream.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIndexation clauses common\u003c\/li\u003e\n\u003cli\u003eBrent c.86 USD\/bbl (2024)\u003c\/li\u003e\n\u003cli\u003eGBP\/USD c.1.27 (2024)\u003c\/li\u003e\n\u003cli\u003ePass-through lag 2–6 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated API\/CMO supply raises switching costs; tech-transfer delays and pass-through lag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliance relies on a concentrated pool of certified API\/CMO suppliers (China\/India majority by 2024), raising switching costs and supplier price leverage. Certified dossiers, warning-letter risk and tech-transfer delays (6–12 months in 2024) further strengthen suppliers. Tooling ($50k–250k), lead times (12–26 weeks), royalties (5–12%) and indexation push costs; pass-through lags 2–6 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI supply concentration\u003c\/td\u003e\n\u003ctd\u003eChina\/India majority\u003c\/td\u003e\n\u003ctd\u003eLimited alternatives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech-transfer delay\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003ctd\u003eHigher switching cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTooling\u003c\/td\u003e\n\u003ctd\u003e$50k–250k\u003c\/td\u003e\n\u003ctd\u003eCapex barrier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead times\u003c\/td\u003e\n\u003ctd\u003e12–26 weeks\u003c\/td\u003e\n\u003ctd\u003eLocked supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty rates\u003c\/td\u003e\n\u003ctd\u003e5–12%\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrent \/ FX\u003c\/td\u003e\n\u003ctd\u003e$86 \/ GBPUSD 1.27\u003c\/td\u003e\n\u003ctd\u003eInput cost volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePass-through lag\u003c\/td\u003e\n\u003ctd\u003e2–6 months\u003c\/td\u003e\n\u003ctd\u003eWorking capital strain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive Porter's Five Forces analysis tailored to Alliance Pharma, uncovering competition drivers, buyer\/supplier power, substitutes and entry barriers, identifying disruptive threats and strategic levers to protect market share; fully editable for use in investor decks, business plans, or internal strategy documents.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet for Alliance Pharma that maps supplier\/buyer power, threat of generics, regulatory pressure and competitive rivalry—perfect for quick strategic pivots and boardroom decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated retail and wholesale channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge pharmacy chains, grocers and wholesalers exert strong leverage: Kantar 2024 shows Tesco 27.1%, Sainsbury 14.9%, Asda 14.2% and Morrisons 9.6% of UK grocery sales—about 66% combined—enabling demands for rebates and slotting fees. Boots, with roughly 2,200 UK outlets in 2024, and major wholesalers use category captaincy to shape shelf space and pricing. Consolidation has amplified negotiating clout, forcing Alliance to offer competitive trade terms and actionable POS and sales data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice-sensitive consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOTC consumers switch rapidly to private label—own‑label penetration in UK grocery reached around 50% in 2024, so Alliance Pharma faces quick churn on price. Elasticity is high in commoditized OTC categories, with promotions and digital coupons driving double‑digit short‑term volume uplifts. Brand equity must justify consistent price premiums to avoid margin erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and hospital formularies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers and hospital formularies gate access and net pricing for Alliance Pharma Rx lines; the NHS medicines bill is c.£20bn (2023\/24), concentrating negotiating power. Tender dynamics in hospitals compress margins—procurement drives price reductions often exceeding 30% for competing products. Robust clinical and pharmacoeconomic evidence is required to defend formulary position, as delistings can trigger abrupt \u0026gt;50% volume loss.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eE-commerce marketplaces transparently benchmark prices, accelerating shopper comparison and pressuring margins as algorithms favor velocity and deep discounts; platforms often levy referral and ad fees averaging 15–20% which amplifies effective buyer power. Chargebacks (~0.5–0.8% dispute rate) and dispute costs (~$25–$50 per case) further erode margins. DTC can offset platform power but in 2024 customer acquisition costs rose ~15–25%, requiring heavier performance marketing spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eMarketplace referral\/ad fees: 15–20%\u003c\/li\u003e\n\u003cli\u003eChargeback rate: ~0.5–0.8%; cost per dispute: $25–$50\u003c\/li\u003e\n\u003cli\u003ePerformance marketing CAC increase 2024: ~15–25%\u003c\/li\u003e\n\u003cli\u003eAlgorithms favor velocity\/discount depth → price transparency ↑\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn smaller markets international distributors often aggregate demand and secure territorial exclusivity covering roughly 50–70% of local volumes in 2024, increasing their bargaining power. They commonly push for extended credit terms (60–90 days) and demand marketing support, raising Alliance Pharma’s working capital needs. Regulatory approvals and logistical transitions typically take 6–12 months, making partner switching costly; enforceable performance clauses can rebalance leverage and cut disputes by ~30% when applied.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExclusivity: 50–70% market share\u003c\/li\u003e\n\u003cli\u003eCredit terms: 60–90 days\u003c\/li\u003e\n\u003cli\u003eSwitching cost: 6–12 months\u003c\/li\u003e\n\u003cli\u003ePerformance clauses: ~30% fewer disputes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate label \u003cstrong\u003e~50%\u003c\/strong\u003e, NHS budget \u003cstrong\u003ec.£20bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge UK chains and wholesalers (Tesco 27.1%, Sainsbury 14.9%) exert strong leverage, forcing rebates and slotting fees. OTC private label ~50% penetration and high price elasticity compress margins; NHS medicines bill c.£20bn gives payers procurement power. Marketplaces charge 15–20% fees; international distributors take 50–70% exclusivity and demand 60–90 day credit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesco share\u003c\/td\u003e\n\u003ctd\u003e27.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate label\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHS budget\u003c\/td\u003e\n\u003ctd\u003ec.£20bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketplace fees\u003c\/td\u003e\n\u003ctd\u003e15–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor exclusivity\u003c\/td\u003e\n\u003ctd\u003e50–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAlliance Pharma Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Alliance Pharma Porter’s Five Forces Analysis you’ll receive—no placeholders or samples. The full document is fully formatted, professionally written and ready for immediate download upon purchase. You’re viewing the final deliverable, identical to the file delivered after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163343892857,"sku":"alliancepharmaplc-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/alliancepharmaplc-five-forces-analysis.png?v=1762717853","url":"https:\/\/portersfiveforce.com\/products\/alliancepharmaplc-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}